References
- Bell DS. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813–1827.
- Insulin degludec (Tresiba)–a new long-acting insulin for diabetes. Med Lett Drugs Ther. 2015;57(1483):163–164.
- Kim ES, Plosker GL. AFREZZA® (insulin human) inhalation powder: a review in diabetes mellitus. Drugs. 2015;75(14):1679–1686.
- Albright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care. 2004;27(2):632–633.
- Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract. 2008;14(1):112–124.
- O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007;100(5):899–904.
- Bell DS, Ovalle F. Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocr Pract. 2000;6(5):357–360.
- Binder E, Lange O, Edlinger M, et al. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2015;123(4):260–264.